Home / Congress Presentations / Geographic Atrophy / The Association for Research in Vision and Ophthalmology (ARVO) 2024
Landing
Association for Research in Vision and Ophthalmology (ARVO) 2024
Long-term efficacy and safety of pegcetacoplan over 36 months: results from 12 months of the GALE open-label extension study
SD-OCT and Fundus Autofluorescence in geographic atrophy: a comprehensive point-to-point correlation of FAF and SD-OCT using the phase III DERBY and OAKS trials
Variability of perilesional FAF patterns associated with automated OCT-based PR/RPE loss ratios in GA progression in the phase 3 OAKS/DERBY trials
Contrast sensitivity function using a prototype gaze tracking-based virtual reality headset in age-related macular degeneration
Prevalence of outer retinal tubulation (ORT) and association with geographic atrophy (GA) lesion growth among GA patients in the OAKS and DERBY trials
A deep-learning approach to identifying quantitative OCT biomarkers predictive of visual deficit measured by microperimetry at 24 months in OAKS trial
AI-based qOCT analysis of phase-III trials OAKS & DERBY data on the effect of pegcetacoplan on geographic atrophy
Predictive value of the photoreceptor/RPE loss ratio on OCT in the management of geographic atrophy (GA) for patient selection and monitoring of therapeutic efficacy
Loss of independence in geographic atrophy: results from the MOSAIC study among patients and their caregivers in Europe, Canada, and Australia
Deep learning based segmentation of geographic atrophy in fundus autofluorescence: external validation in imaging acquired in a clinical trial
Pegcetacoplan vs avacincaptad pegol in geographic atrophy: an anchored matching-adjusted indirect comparison of three phase 3 trials
Rate of response to treatment in eyes with GA treated with Pegcetacoplan in a within-patient comparison using automated AI-based OCT biomarker quantifications in OAKS and DERBY
IRIS® Registry analysis of anti-VEGF treatment in patients with coexisting neovascular age-related macular degeneration and geographic atrophy
Pegcetacoplan delays time to development of central scotoma loss of central macular sensitivity: a microperimetry analysis of the phase 3 OAKS study
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.